Lakshmi Nair, NP
Psychiatric/Mental Health · Peoria, AZNPI 1720588742
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $17,820 of the $24,494 with a category attached, or 72.8%. Johnson & Johnson accounts for 88.5% of it on its own, with 13 other manufacturers making up the rest. 2025 is the largest year on record at $22,481, more than ten times the $350 reported in 2021. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $176.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$22K
- AbbVie$571
- Alkermes, Inc.$520
- E.r. Squibb & Sons, L.L.C.$312
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$288
- Neurocrine Biosciences, Inc.$216
- plus $918 from 8 others
What the payments were for
- Speaking & faculty fees$17,82073%
- Travel & lodging$2,50710%
- Food & beverage$4,16717%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 36 | $21,668 |
| AbbVie(2 entities) | 27 | $571 |
| Alkermes, Inc. | 13 | $520 |
| E.r. Squibb & Sons, L.L.C. | 5 | $312 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 10 | $288 |
| Neurocrine Biosciences, Inc. | 10 | $216 |
| Janssen Scientific Affairs, LLC | 2 | $202 |
| Otsuka America Pharmaceutical, Inc. | 9 | $193 |
| Teva Pharmaceuticals USA, Inc. | 10 | $187 |
| Lundbeck LLC | 5 | $94 |
| Indivior Inc. | 3 | $87 |
| Braeburn Inc. | 3 | $68 |
| Corium, LLC | 5 | $67 |
| Axsome Therapeutics, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$21,311
- INVEGA TRINZA$20,564
- ARISTADA$470
- LYBALVI$419
- COBENFY$247
- CAPLYTA$129
- STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS$128
- ARISTADA INITIO$118
- SPRAVATO$108
How this compares
$24,494 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 72 | $246,977 |
| IngrezzaValbenazine Tosylate | 29 | $243,723 |
| AristadaAripiprazole Lauroxil | 30 | $94,200 |
| LybalviOlanzapine/Samidorphan Malate | 49 | $80,548 |
| AustedoDeutetrabenazine | 18 | $66,764 |
| RexultiBrexpiprazole | 40 | $63,524 |
| Austedo XrDeutetrabenazine | 11 | $55,402 |
| VraylarCariprazine Hcl | 31 | $50,635 |
| Risperdal ConstaRisperidone Microspheres | 35 | $44,489 |
| CaplytaLumateperone Tosylate | 24 | $41,758 |
| TrintellixVortioxetine Hydrobromide | 18 | $13,428 |
| Chlorpromazine Hcl | 37 | $13,325 |
| SeroquelQuetiapine Fumarate | 24 | $12,795 |
| Divalproex Sodium ErDivalproex Sodium | 142 | $12,366 |
| Lurasidone Hcl | 88 | $9,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $21,668 | $291,466107 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $216 | $243,72329 claims |
| Alkermes, Inc.Aristada, Lybalvi | $520 | $174,74779 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $187 | $122,16629 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $193 | $63,52440 claims |
| AbbVieVraylar | $571 | $50,63531 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $288 | $41,75824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Other psychiatric/mental health in Peoria
- Jeffrey EdelmanPeoria$53K
- Elizabeth ElliottPhoenix$363K
- Diane StrickerGilbert$281K
- Russell HorningPhoenix$254K
- Stacy UnderwoodMesa$252K
- Brett LeifsonScottsdale$90K
- Claire ReecePhoenix$88K
- Bryan LazaroScottsdale$61K
- Luis FongPhoenix$59K
- Jesika McKenzieMesa$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.